Mineralys Therapeutics, Inc. presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2-5. In this new analysis, investigators identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure (BP) of 32 millimeters of mercury (mmHg). Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.58 USD | -0.87% |
|
-4.26% | +46.28% |
Jun. 14 | Mineralys Therapeutics, Inc. Announces Changes to its Board | CI |
Jun. 13 | Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.28% | 625M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting